Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Health Care Sector · Guggenheim

Health Care Fund Investor Class (RYHIX)

Ticker RYHIX · · Holdings as of Jun 30, 2026

Expense ratio
1.38%$138/yr per $10k
5-yr return
+5.1%annualized
1-yr return
+14.4%as of Dec 2025
Net assets
$19.4Mall share classes
Holdings
135

Bottom line

Is RYHIX a good fund? The bottom line

RYHIX is the Investor Class share class of Health Care Fund, an actively managed health care sector mutual fund from Guggenheim.

Annual fees run 1.38% — about $138 a year on every $10,000 invested, more expensive than 77% of health care sector funds we track.

It returned +14.4% over one year, +5.1% a year over five years, +7.9% a year over ten (as of Dec 31, 2025, per its prospectus).

With $19.4 million in net assets and 135 holdings, its largest position is Eli Lilly & Company (3.6%) and the top 10 make up 20.6% of the portfolio.

The closest lower-cost alternative we found is XLV (0.08%, 79% top-holdings overlap).

What to watch

  • Expensive for its category (1.38%)
  • Small fund ($19.4 million) — small funds are likelier to close
  • High turnover (244% a year) can mean more taxable distributions

Updated Nov 19, 2026

What RYHIX invests in

The Health Care Fund (the Fund) seeks to provide capital appreciation by investing in companies that are involved in the health care industry (Health Care Companies).

Under normal circumstances, the Fund invests substantially all (at least 80%) of its net assets in equity securities of Health Care Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. The Advisor employs a proprietary quantitative and qualitative methodology to identify Health Care Companies in which to invest. The methodology utilizes screens based on price, liquidity, and tradability. The securities are then weighted using a proprietary modified capitalization weighting methodology. The portfolio may be further adjusted to comply with regulatory investment limitations or as determined appropriate by the Advisor. The Fund may invest to a significant extent in the securities of Health Care Companies that have small to mid-sized capitalizations. Health Care…

From the fund's prospectus (filed Jul 29, 2026).

RYHIX performance

Fund calendar-year total returns, 2016–2025 2016: −9.4%; 2017: +23.5%; 2018: +1.6%; 2019: +22.8%; 2020: +18.9%; 2021: +19.2%; 2022: −11.6%; 2023: +5.8%; 2024: +0.6%; 2025: +14.4% −9% 2016 +23% 2017 +2% 2018 +23% 2019 +19% 2020 +19% 2021 −12% 2022 +6% 2023 +1% 2024 +14% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
RYHIX+14.4%+5.1%+7.9%
Health Care Sector median+14.5%+4.2%+7.9%

Source: Fund prospectus, as of Dec 31, 2025

Full RYHIX performance history →

What RYHIX costs

On a $10,000 investment, RYHIX's 1.38% expense ratio costs about $138 a year. The prospectus estimates $1,709 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full RYHIX fee table →

RYHIX top 10 holdings

#Holding% of fund
1Eli Lilly & Company LLY3.63%
2Johnson & Johnson JNJ2.88%
3Abbvie Inc ABBV2.52%
4Unitedhealth Group Inc UNH2.22%
5Merck & Company Inc MRK2.04%
6Thermo Fisher Scientific Inc TMO1.61%
7Amgen Inc AMGN1.56%
8Abbott Laboratories ABT1.42%
9Gilead Sciences Inc GILD1.39%
10Vertex Pharmaceuticals Inc VRTX1.34%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 20.6% of the fund. See all top 25 holdings and asset mix →

Alternatives to RYHIX

Closest equivalent at other fund companies
FamilyFundExpense ratioOverlap
SPDR (State Street)XLV State Street(R) Health Care Select…0.08%79% Compare
FidelityFHLC Fidelity MSCI Health Care Index ETF0.084%80% Compare
VanguardVHT Vanguard Health Care Index Fund0.09%81% Compare
iSharesIYH iShares U.S. Healthcare ETF0.37%76% Compare
J.P. MorganJDOC JPMorgan Healthcare Leaders ETF0.65%64% Compare
SchwabSWHFX Schwab Health Care Fund0.8%66% Compare

More funds like RYHIX →

RYHIX FAQ

What is the expense ratio of RYHIX?
RYHIX's expense ratio is 1.38%, which works out to about $138 a year for every $10,000 invested. The prospectus estimates total costs of $1,709 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is RYHIX a good investment?
It depends on your goals, but the data points to: expensive for its category (1.38%); small fund ($19.4 million) — small funds are likelier to close; high turnover (244% a year) can mean more taxable distributions. This is general information, not personalized advice.
What does RYHIX hold?
RYHIX's largest holdings are Eli Lilly & Company (3.6%), Johnson & Johnson (2.9%), Abbvie Inc (2.5%), Unitedhealth Group Inc (2.2%), Merck & Company Inc (2.0%). It holds 135 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is RYHIX's 5-year return?
RYHIX returned +5.1% a year over the five years ending Dec 31, 2025, and +7.9% a year over ten years. Past performance does not guarantee future results.
What is a cheaper alternative to RYHIX?
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) overlaps about 79% with RYHIX and charges 0.08%.
Who manages RYHIX?
RYHIX is offered by Guggenheim through Rydex Series Funds.